Korean J Gastroenterol.  2002 Aug;40(2):81-87.

Efficacy of New Anti-viral Agent in the Treatment of Chronic Hepatitis B

Affiliations
  • 1Institute for Digestive Research, Soon Chun Hyang University College of Medicine, Seoul, Korea. schkys@hosp.ac.kr

Abstract

The aims of antiviral therapy for chronic hepatitis B are to sustain suppression of hepatitis B virus (HBV) replication and to achieve remission of liver disease activity. Currently, interferon- and lamivudine have been approved by the FDA for the treatment of chronic hepatitis B. However, the efficacy of interferon- is limited to a small percentage of patients, and many adverse effects of the treatment exist. A major drawback of continued lamivudine therapy is the high incidence of drug-resistant mutant. Several antiviral drugs such as adefovir dipivoxil, entecavir, clevudine, and emtricitabine are under clinical investigation as the potential agents for mono- or combination therapy, which have been shown to be highly effective for chronic hepatitis B. Especially, some of them have a strong antiviral effect against lamivudine-resistant mutant as well as wild-type HBV. Long-term treatment with adefovir dipivoxil does not lead to the emergence of resistant virus. Combination therapy seems to represent the future treatment for chronic hepatitis B because of its antiviral synergistic effect and minimal incidence of drug-resistant mutant, but the choice of agents for combination therapy needs further study.

Keyword

Hepatitis B; Chronic; Adefovir dipivoxil; Entecavir; Clevudine; Emtricitabine
Full Text Links
  • KJG
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr